1. Newsroom
  2. Swiss equities: sustained growth driven by emerging countries
Menu
UBP in the press 06.02.2018

Swiss equities: sustained growth driven by emerging countries

Swiss equities: sustained growth driven by emerging countries

Contrary to some small- & mid-cap (SMID) segments of stock indices, the SPI Extra is not necessarily more of a reflection of the domestic economy than the wider Swiss equity market, where more than 90% of company revenues are generated abroad. Swiss SMIDs are broadly as international.


With a high proportion of industrial companies listed in this size bracket, it comes as no surprise that the current synchronised global growth is a positive for SMIDs from Switzerland. Of particular interest currently is the high exposure these companies have to emerging markets. Looking at the location of the final product to which a Swiss company contributes, more than 30% will be in emerging markets.

With leadership positions in niche, often mission-critical technologies, Swiss SMID companies are likely to benefit from improved industrial demand in major end markets, such as China. As demand shifts here from basic infrastructure build, which is more supportive for the materials sector, which is under-represented in Switzerland, to more added-value industries, this begins to appear in the expectations and order entries of Swiss SMIDs. An interesting example is the Chinese initiative to support a domestic semiconductor industry. Observations have been made of factory constructions and road networks around these. In the near future we expect to see the machinery orders picking up, which will be favourable for suppliers to this sector, such as VAT Group, Comet or Inficon.

Improved consumer demand in emerging markets is similarly supportive to Swiss SMIDs. The continued appetite for safer products, notably in the food and pharmaceutical sectors, offers opportunities for DKSH’s distribution activities and food and pharmaceutical companies such as Hochdorf, who has expectations of significant growth for their high-end baby milk powder in China.

Swiss SMID companies have a history of adapting to industrial relocalisation. Indeed, Switzerland’s textile industry is no longer on the banks of the Rhine. Nevertheless, Swiss textile machinery companies are global leaders and at the forefront of this recovering industry in China and Turkey. Just over the last few days, Oerlikon has secured two significant orders from China. Indeed, Oerlikon is a good example of a Swiss company which is considered domestic in other markets, due to its high level of intergration and ability to adapt to local conditions. Rieter, another textile machinery champion, has indicated a clear pick-up in activity in Turkey as credit conditions become easier there.

These examples demonstrate the good diversification of Swiss SMIDs. They participate fully in global growth opportunities. We tend to over-allocate to this size of companies in our all-cap strategies and also offer a fund which invests solely in Swiss SMIDs. Our Swiss & global equity funds look to invest in companies delivering improving Cash Flow Returns on Investment (CFROIs), and this is precisely what we are seeing in Swiss SMIDs currently. Swiss SMIDs were slower to emerge from the financial crisis, potentially due to an expectation that they would find it harder to maintain or improve their CFROIs due to the strong franc. In fact, they were faster and more innovative in combating this headwind than some of their larger peers. The catch-up in performance that we have seen over the last 18 months, leading the SMIDs to regain their valuation premium to large caps, reflects improving CFROIs, contrary to what we are seeing in the large-cap sector. Some of this improvement can also be attributed to improved earnings coming from the global synchronised growth and better revenue generation in emerging markets in particular.

Demand-driven (or sales growth-driven) earnings improvement is just starting to pick up since the financial crisis, especially in Europe and emerging markets. Although it may be ambitious to expect a similar stock market performance in 2018 to the stellar 27% gained by Swiss SMIDs in 2017, it does seem realistic to expect low to mid double-digit earnings growth, enhanced by a dividend yield of around 2.5%, leading to a potential performance of 15–20% for the SPI Extra in 2018.

More about SMIDs Caps

TAYLOR JOLIDON Eleanor.jpg

Eleanor Taylor Jolidon
Co-Heads Swiss & Global Equities

MOELLER Martin.jpg

Martin Moeller
Co-Heads Swiss & Global Equities

Newsletter

Sign up to receive UBP’s latest news & investment insights directly in your inbox

Click and enter your email address to subscribe

Most read

UBP in the press 18.10.2018

Tech sector driven by innovation

Sphere (10.2018) - Since the 2008-09 global financial crisis, the global technology sector has delivered an impressive annual return of 15.4%, easily outpacing global equities as a whole (10.2%).

UBP in the press 26.09.2018

Asset TV Fund Selector: Fixed Income

What does the end of quantitative easing mean for bond investors? What should be the right exposure to emerging bond markets and why are active managers better equipped than passive ones to handle the return of volatility? Mohammed Kazmi, Portfolio Manager & Macro-Strategist Global and Absolute Return Fixed Income at UBP, recently participated in an Asset TV broadcast outlining the risk and reward trade-offs in fixed-income markets over the next six to twelve months.

UBP in the press 28.09.2018

AI will benefit Swiss banks

Bilan (25.09.2018) - “If I had to bet on which would be the leading professions in the years to come, Swiss bankers would be on the list!” This prediction by Laurent Alexandre, the founder of the Doctissimo.fr website, may come as a surprise to some.


Further reading

UBP in the press 12.12.2018

Innovation creates opportunities in healthcare

Bilan (12.12.2018) - The secular trends in healthcare – ageing populations, emerging market demand, and expanding basic health insurance – remain well entrenched. However, investors should shift their focus towards differentiated innovators in the healthcare space via mid-sized biotech and medical technology (like Swiss companies Lonza and Galapagos, for example), and healthcare-focused IT companies (such as Teleadoc).

UBP in the press 03.12.2018

It’s all in the family for Union Bancaire Privée's de Picciotto

The Straits Times (25.11.2018) - As times change, CEO’s ambition is to make UBP one of the biggest family-owned banks.

UBP in the press 27.11.2018

A new era begins for investing wealth

Forbes Middle East (22.11.2018) - Tougher regulations, tax declarations and transparency trends are significantly reshaping the private banking industry, and the Middle East is no exception to this.